# Platelet Disorders and Genetic Vaccines: Exploring Potential Links
Written on
Chapter 1: Introduction to Genetic Vaccines and Platelet Disorders
This article aims to clarify the often-misunderstood relationship between genetic vaccines and platelet disorders. While some may perceive this content as fueling vaccine hesitancy, the intention is to alleviate concerns by examining the scientific basis for any potential risks.
Genetic vaccines, including the mRNA vaccines from Pfizer-BioNTech and Moderna, as well as the DNA vaccine from Oxford/AstraZeneca (Ox/AZ), differ fundamentally from traditional vaccines. Unlike conventional vaccines that do not penetrate cells, genetic vaccines deliver genetic material directly into cells. This mRNA or DNA instructs the cells to produce pathogen-specific proteins—like the spike proteins of SARS-CoV-2—to prepare the immune system for future encounters with the virus.
Section 1.1: Understanding the Mechanism of Genetic Vaccines
The mRNA vaccines utilize lipid nanoparticles (LNPs) for efficient delivery, while the DNA vaccine employs harmless adenoviruses. As of March 31, 2021, the European Medicines Agency (EMA) reported 62 instances of cerebral venous sinus thrombosis (CVST) accompanied by low platelet counts among the 9.2 million doses of the Ox/AZ vaccine administered. Notably, 44 of these cases occurred in Europe, with 14 resulting in fatalities, predominantly affecting younger women.
Although the occurrence rate of 6.7 CVST cases per million doses is slightly above the expected incidence of 5 cases per million annually, it is important to consider that CVST may have been underreported prior to the pandemic. Consequently, several countries, including Germany and Sweden, have restricted the use of the Ox/AZ vaccine to older individuals, while Denmark and Norway have completely halted its use, despite the EMA's assertion that there is no definitive evidence to support such measures.
Section 1.2: Insights from Recent Studies
A recent commentary in the Journal of Hematology identified 20 cases of immune thrombocytopenia (ITP) following the administration of Pfizer-BioNTech and Moderna mRNA vaccines in the U.S. As of February 2, 2021, these cases were observed among over 20 million vaccinated individuals, with 17 cases occurring in individuals with no prior history of ITP. While the incidence appears concerning, the annual estimate of 39,000 to 78,000 cases aligns with the baseline incidence of ITP in the U.S. at approximately 50,000 cases per year. Despite numerous hospitalizations, only one death in New York has been reported.
It is crucial to approach these findings with caution. The authors of the commentary emphasized that it is not entirely dismissible that the Pfizer and Moderna vaccines might, in rare circumstances, provoke new cases of ITP.
Chapter 2: Theoretical Mechanisms Behind Possible Vaccine Effects
Theoretical frameworks have emerged regarding how mRNA vaccines may, in rare instances, trigger ITP. Dr. Goh Kiang-Hua, a consultant general surgeon, suggested that lipid nanoparticles could potentially deliver mRNA into megakaryocytes—the cells responsible for platelet production.
Dr. Hamid A. Merchant, a subject leader in pharmacy, proposed that other viral infections, including influenza and HIV, can infect megakaryocytes and platelets, leading to immune responses that destroy these cells. There is emerging evidence suggesting that SARS-CoV-2 may also interact with platelets via the ACE2 receptor, contributing to clotting disorders in COVID-19 patients.
Merchant posited that genetic vaccines might similarly affect platelets and megakaryocytes, resulting in platelet destruction and subsequent conditions such as thrombocytopenia or hemorrhage. However, it is worth noting that while megakaryocytes possess multiple nuclei, platelets are anucleate and cannot transcribe DNA.
Section 2.1: Exploring Autoimmune Responses
Dr. Merchant has also suggested that auto-reactive antibodies formed after vaccination could mistakenly target platelets. Research has detected such antibodies in COVID-19 patients exhibiting clotting disorders. It is plausible that antibodies generated against spike proteins, whether from vaccination or natural infection, could attack platelets.
Recent findings from Norwegian researchers indicated the presence of an antibody in vaccinated individuals believed to play a role in platelet destruction and subsequent thrombotic events. However, these findings remain preliminary.
Chapter 3: Investigating Vaccine Biodistribution
Despite the well-documented safety and efficacy of genetic vaccines, research on their biodistribution—where the vaccine components travel within the body—remains limited. The EMA has observed that low mRNA levels can be detected in various tissues following administration, although the implications of this distribution for megakaryocytes and platelets are still under scrutiny.
Section 3.1: mRNA vs. DNA Vaccines
Dr. Merchant has noted that the viral load in vaccines is significantly high, suggesting that viral particles are unlikely to remain confined to the injection site. The EMA's reports indicate that while the highest concentrations of viral vectors are found at the injection site, there is some distribution to other tissues.
Closing Remarks
In summary, while potential biological mechanisms may explain the estimated cases of platelet disorders linked to genetic vaccines, the risks remain exceedingly low. This discussion is largely speculative, and definitive evidence supporting these hypotheses is lacking.
Even if genetic vaccines could induce spike protein expression in platelets or megakaryocytes, the actual risk of significant harm appears minimal. It is essential to exercise caution, particularly for individuals with a history of blood disorders.
Ultimately, the focus should remain on the critical risks posed by COVID-19 itself, which has proven fatal for many. The speculative risks associated with genetic vaccines should not overshadow the known dangers of the disease they aim to prevent.